알파 이미터 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 방사성 핵종 유형별(아스타틴, 라듐, 악티늄, 납, 비스무트, 기타), 의료 용도별, 지역별, 경쟁 시장별(2020-2030년)
Alpha Emitter Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Type of Radionuclide (Astatine, Radium, Actinium, Lead, Bismuth, Other), By Medical Application, By Region & Competition, 2020-2030F
상품코드:1692179
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
알파 이미터 세계 시장은 2024년 4억 6,610만 달러에 달할 것으로 예상되며, 2030년까지 연평균 9.80%로 예측 기간 동안 강력한 성장이 예상됩니다.
알파 이미터 세계 시장은 핵의학과 방사선 치료라는 광범위한 분야 중 전문 분야입니다. 알파 입자를 방출하는 방사성 동위원소인 알파 방출 핵종의 생산, 유통, 응용을 중심으로 전개됩니다. 그 배경에는 질병의 확산, 암 환자 증가, 고령화 인구 증가 등이 있습니다. 예를 들어, 국제암연구소(IARC)는 2040년까지 전 세계 암 환자 수는 2,750만 명으로 증가하고, 암 관련 사망자 수는 1,630만 명에 달할 것으로 예측했습니다. 또한, 2022년 8월 Radiation 저널에 게재된 논문에서는 전이성 거세 저항성 전립선암에 대한 라듐223 요법의 최적 사용법을 모색하는 일본 근대의대 과학자들의 연구가 소개되었습니다. 이 연구는 Ra-223의 조기 투여가 전체 생존기간(OS)을 유의하게 개선하는 것으로 나타났으며, 새로운 호르몬 요법이나 항암제 치료 전에 Ra-223을 사용하는 것의 잠재적 이점을 강조했습니다. 알파선 방출 핵종은 독특한 특성으로 인해 의료, 산업, 에너지 분야에서 각광을 받고 있으며, 시장은 괄목할만한 성장과 혁신을 경험하고 있습니다. 양성자 2개와 중성자 2개로 구성된 알파 입자가 방출되기 때문입니다. 이 입자는 높은 전하를 띠고 조직 내 비행거리가 짧아 국소 치료에 효과적입니다. 알파선은 강력하여 주변의 건강한 조직을 보존하면서 정확하게 암세포에 손상을 입혀 파괴할 수 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모(2024년)
4억 6,610만 달러
시장 규모(2030년)
8억 1,037만 달러
CAGR(2025-2030년)
9.80%
급성장 부문
난소암
최대 시장
북미
시장 성장 촉진요인
핵의학에 대한 수요 증가
주요 시장 이슈
규제상의 장애물
주요 시장 동향
표적 α 입자 치료의 발전:
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 알파 이미터 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
방사성 핵종 유형별(아스타틴(At-211), 라듐(Ra-223), Aktinium(Ac-225), 납(Pb-212), 비스무트(Bi-212), 기타)
의료 용도별(전립선암, 골전이, 난소암, 췌장암, 내분비 종양, 기타)
지역별
기업별(2024년)
시장 맵
제6장 북미의 알파 이미터 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 알파 이미터 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 알파 이미터 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 남미의 알파 이미터 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 알파 이미터 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
제11장 시장 역학
성장 촉진요인
제11장 2개 과제
제12장 시장 동향과 발전
최근 동향
제품 출시
인수합병(M&A)
제13장 세계의 알파 이미터 시장 : SWOT 분석
제14장 경쟁 구도
Actinium Pharmaceutical Inc.
Alpha Tau Medical Ltd
Bayer AG
Fusion Pharmaceuticals
IBA Radiopharma Solutions
RadioMedix Inc.
Telix Pharmaceuticals Ltd
Novartis International AG
Isotopen Technologien Munchen AG(ITM)
NorthStar Medical Radioisotopes
제15장 전략적 제안
제16장 리서치사에 대해 & 면책사항
LSH
영문 목차
영문목차
Global Alpha Emitter Market Was valued at USD 466.10 million in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 9.80% through 2030. The Global Alpha Emitter Market is a specialized sector within the broader field of nuclear medicine and radiation therapy. It revolves around the production, distribution, and application of alpha-emitting radionuclides, which are radioactive isotopes emitting alpha particles. This is ascribed due to the growing disease prevalence, growing cancer cases, rising aging population, etc. For instance, the International Agency for Research on Cancer (IARC) projects that by 2040, the global cancer burden will rise to 27.5 million new cases and 16.3 million cancer-related deaths, largely due to population growth and aging. Additionally, an August 2022 article in the Radiation journal featured research by a Kindai University scientist in Japan exploring the optimal use of Radium-223 therapy for Metastatic Castration-Resistant Prostate Cancer. The study indicated that early administration of Ra-223 significantly improved overall survival (OS), highlighting potential advantages of using Ra-223 before novel hormonal or anticancer treatments. Alpha emitters have gained prominence in medical, industrial, and energy sectors due to their unique characteristics, and the market is experiencing notable growth and innovation. Due to the release of alpha particles, which consist of two protons and two neutrons. These particles are highly charged and have a short range in tissue, making them effective for localized therapy. Alpha radiation is potent, capable of damaging and destroying cancer cells with precision while sparing nearby healthy tissue.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 466.10 Million
Market Size 2030
USD 810.37 Million
CAGR 2025-2030
9.80%
Fastest Growing Segment
Ovarian Cancer
Largest Market
North America
Key Market Drivers
Growing Demand for Nuclear Medicine
One of the primary drivers of the Global Alpha Emitter Market is the increasing demand for nuclear medicine. Advances in medical science have revealed the efficacy of alpha emitters in targeted cancer therapy. Alpha particles are highly effective at killing cancer cells, making them a vital component of radiopharmaceuticals used in cancer treatment. The shift towards precision medicine is another key reason for the growing demand. Medical professionals are increasingly tailoring treatments to individual patients, and alpha emitters offer a precise way to target cancerous cells while minimizing damage to healthy tissue. The global rise in cancer cases is a significant driver. As cancer incidence continues to increase, the demand for effective treatment options also grows. Alpha emitters provide a promising solution for certain types of cancers that are challenging to treat through conventional methods. Ongoing clinical trials and research efforts are further fueling demand. Pharmaceutical companies and research institutions are investing heavily in the development of new alpha-emitting radiopharmaceuticals, expanding the range of treatable conditions. Increasing patient awareness and advocacy groups' efforts have contributed to the demand for nuclear medicine. Patients and their families are seeking out cutting-edge treatments, and alpha emitter-based therapies are becoming more accessible and sought after.
Key Market Challenges
Regulatory Hurdles
Regulatory hurdles, such as stringent licensing and safety regulations, can significantly impede the growth of the Global Alpha Emitter Market. Governments and regulatory bodies closely monitor the use and transport of radioactive materials, including alpha emitters, due to safety concerns. This leads to lengthy approval processes and strict compliance requirements. The highly radioactive nature of alpha emitters necessitates rigorous oversight to prevent accidents and ensure public safety. However, the complexity and stringency of regulatory processes can slow down the development and commercialization of alpha-emitting products. Companies may face delays and increased costs in navigating the regulatory landscape, hindering market growth.
Key Market Trends
Advancements in Targeted Alpha-Particle Therapy:
A significant trend in the Global Alpha Emitter Market is the continuous advancements in targeted alpha-particle therapy. This therapy involves the use of alpha-emitting radiopharmaceuticals to precisely target and destroy cancer cells while sparing healthy tissue. Recent research and development efforts have led to the creation of novel alpha-emitting compounds that are more effective and have reduced side effects. This trend is driven by the increasing focus on personalized medicine in oncology. Healthcare providers and pharmaceutical companies are investing in research to develop alpha emitters that can be tailored to a patient's specific cancer type and genetic profile. As a result, targeted alpha-particle therapy is gaining prominence as a promising and minimally invasive treatment option for various cancers, including prostate, bone, and pancreatic cancer.
Key Market Players
Actinium Pharmaceutical Inc.
Alpha Tau Medical Ltd
Bayer AG
Fusion Pharmaceuticals
IBA Radiopharma Solutions
RadioMedix Inc.
Telix Pharmaceuticals Ltd
Novartis International AG
Isotopen Technologien Munchen AG(ITM)
NorthStar Medical Radioisotopes
Report Scope:
In this report, the Global Alpha Emitter Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Alpha Emitter Market, By Type of Radionuclide:
Astatine (At-211)
Radium (Ra-223)
Actinium (Ac-225)
Lead (Pb-212)
Bismuth (Bi-212)
Other
Alpha Emitter Market, By Medical Application:
Prostate Cancer
Bone Metastasis
Ovarian Cancer
Pancreatic Cancer
Endocrine Tumors
Other
Alpha Emitter Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Alpha Emitter Market.
Available Customizations:
Global Alpha Emitter market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Alpha Emitter Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type of Radionuclide (Astatine (At-211), Radium (Ra-223), Actinium (Ac-225), Lead (Pb-212), Bismuth (Bi-212), Other)
5.2.2. By Medical Application (Prostate Cancer, Bone Metastasis, Ovarian Cancer, Pancreatic Cancer, Endocrine Tumors, Other)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Alpha Emitter Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type of Radionuclide
6.2.2. By Medical Application
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Alpha Emitter Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type of Radionuclide
6.3.1.2.2. By Medical Application
6.3.2. Canada Alpha Emitter Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type of Radionuclide
6.3.2.2.2. By Medical Application
6.3.3. Mexico Alpha Emitter Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type of Radionuclide
6.3.3.2.2. By Medical Application
7. Europe Alpha Emitter Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type of Radionuclide
7.2.2. By Medical Application
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Alpha Emitter Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type of Radionuclide
7.3.1.2.2. By Medical Application
7.3.2. United Kingdom Alpha Emitter Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type of Radionuclide
7.3.2.2.2. By Medical Application
7.3.3. Italy Alpha Emitter Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Type of Radionuclide
7.3.3.2.2. By Medical Application
7.3.4. France Alpha Emitter Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type of Radionuclide
7.3.4.2.2. By Medical Application
7.3.5. Spain Alpha Emitter Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type of Radionuclide
7.3.5.2.2. By Medical Application
8. Asia-Pacific Alpha Emitter Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type of Radionuclide
8.2.2. By Medical Application
8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Alpha Emitter Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type of Radionuclide
8.3.1.2.2. By Medical Application
8.3.2. India Alpha Emitter Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type of Radionuclide
8.3.2.2.2. By Medical Application
8.3.3. Japan Alpha Emitter Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type of Radionuclide
8.3.3.2.2. By Medical Application
8.3.4. South Korea Alpha Emitter Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type of Radionuclide
8.3.4.2.2. By Medical Application
8.3.5. Australia Alpha Emitter Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type of Radionuclide
8.3.5.2.2. By Medical Application
9. South America Alpha Emitter Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type of Radionuclide
9.2.2. By Medical Application
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Alpha Emitter Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type of Radionuclide
9.3.1.2.2. By Medical Application
9.3.2. Argentina Alpha Emitter Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type of Radionuclide
9.3.2.2.2. By Medical Application
9.3.3. Colombia Alpha Emitter Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type of Radionuclide
9.3.3.2.2. By Medical Application
10. Middle East and Africa Alpha Emitter Market Outlook
